Therefore, the most effective strategy may be to develop an immunogenic vaccine or vaccines targeting both Aβ and tau, such that the same vaccine or the combination of vaccines would then be effective across the entire spectra of AD progression. The gene discussed is MAPT; the disease is Alzheimer disease.